Talk:Glatiramer acetate
From Wikipedia, the free encyclopedia
 |
This article is within the scope of WikiProject Neurology. Please visit the project page for details or ask questions at the talk page. |
| Start | This page has been rated as Start-Class on the quality assessment scale |
| Mid | This article has been rated as Mid-importance on the importance assessment scale |
 |
Glatiramer acetate is part of WikiProject Pharmacology, a project to improve all Pharmacology-related articles. If you would like to help improve this and other pharmacology articles, please join the project. All interested editors are welcome. |
| Start | This article has been rated as Start-Class on the quality scale. |
|
|
|
 |
This article is within the scope of WikiProject Medicine. Please visit the project page for details or ask questions at the doctor's mess. |
| Start | This page has been rated as Start-Class on the quality assessment scale |
| Mid | This article has been rated as Mid-importance on the importance assessment scale |
Contents |
[edit] Cleanup Standards
The tag on Wiki Cleanup Standards has existed here since January 2007. I think the page has come a long way, and could now be removed.io-io (talk) 17:31, 3 February 2008 (UTC)
[edit] Copyvio
Most of the text is a wikified version of http://www.mult-sclerosis.org/Copaxone.html. Added copyvio notice. SpiceMan (会話) 05:34, 29 November 2006 (UTC)
[edit] Link issues
It says to click on the link to copaxone for more information, but that link just gets redirected back to the glatiramer page. I don't know much about this drug, I'm actually just trying to find more about it in case my latest round of MRIs confirm these demyelenating lesions as MS. The MS page claims that it might act by causing T-cells to attack the glatiramer molecule, rather than myelin, almost like a decoy, but I was hoping to find some of the basic pharmacodynamics and pharmacokinetics here. I am not a physician or researcher in this field, but I would be willing to contribute any information that i come across, if anyone has any suggestions for where to look.
[[User:Hyperion35]
[edit] Efficacy issues
- Disputed Content
The Efficacy section, last paragraph, vaguely refers "to studies with a higher dose of glatiramer acetare ( 40 mg - the FORTE study); studies in Clinically Isolated Syndrome patients (the PreCISe study) as well as numerous combination and induction protocols, in which glatiramer acetate is given together with or following another active product. Recent results from some of the latter studies reveal a very good effect of glatiramer acetate in highly active patients".
However, the FORTE study only started enrolling in 2006, and no results will be available probably until 2009. Also the PreCISe study is not in confirmed MS per se, but in "First Clinical Event Suggestive of MS" patients - neither correspond well to the designation of "highly active patients".
The combination trials are not listed, but without citation it appears equally likely that the "very good effect" may have been the effect not of glatiramer acetate but of the combination drug, as for example new MS candidates are often tested with glatiramer acetate, but also with glatiramer acetate as the control (examples are: Estriol, Tovaxin). In such trials, the effect of glatiramer acetate cannot be measured at all.
Also, what is meant by "a very good effect" to MS patients ? The use of this term is not appropriate to a reference encyclopedia for this drug, particularily as glatiramer acetate's clinical results have been modest compared to other MS disease-modying therapies - see below.
In particular, according to the Cohrane review of Copaxone, an effect in disability progression in MS has never been demonstrated for the drug, a fact which differentiates glatiramer acetate from most other MS disease-modying therapies, but omitted entirely from the Efficacy section. I hesitate to add this fact to the section, as it appears some bias has gone into writing what is there already, especially judging by the final paragraph.
io-io (talk) 00:33, 22 January 2008 (UTC)
UPDATE: As no-one has responded to the Disputed Content tag since placed 2 weeks ago, I have deleted what were clearly idustry marketing statements and added regulatory data, with citations. I have also now removed the Disputed Content tag. io-io (talk) 17:31, 3 February 2008 (UTC)
[edit] Minor issue about regulatory t-cells
"Administration of glatiramer shifts the population of T cells from pro-inflammatory Th1 cells to regulatory Th2 cells that suppress the inflammatory response." Either they're regulatory or they're th2...--GustenNyberg (talk) 21:47, 5 March 2008 (UTC)
